Vitalgen was founded in March 2020 and focused on the delivery of innovative therapeutics to patients to fulfill unmet medical needs. We have in-house developed virus and non-virus drug delivery system and intellectual independent CRISPR gene editing platform for in-vivo and in-vitro applications. Our current pipeline highlighted as AAV gene therapy in which six were in the stage of clinical development to treat adolescent and adult rare diseases in CNS, ophthalmology and hematology with the potentials to be the worldwide first-in-class or best-in-class. We have raised up to 800 million RMB in a series of fundraising with VCs e.g. IDG and Hillhouse and looking forward to participating BIO-Europe in 2024 for any collaborations with potential partners. Vitalgen has established multiple collaborations with partners in CRISPR therapeutic application, aav production and CRISPR protein manufacturing, we are looking forward to global partners in the development and commercialization of our clinical stage pipelines.